Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

Market Cap	27.37B
Revenue (ttm)	5.76B
Net Income (ttm)	1.40B
Shares Out	2.23B
EPS (ttm)	0.63
PE Ratio	19.51
Forward PE	16.17
Dividend	0.27 (2.20%)
Ex-Dividend Date	May 22, 2024

Volume	43,014,300
Average Volume	28,408,112
Open	12.30
Previous Close	12.29
Day's Range	12.22 - 12.43
52-Week Range	9.08 - 18.33
Beta	0.20
RSI	48.88
Earnings Date	Apr 22, 2025

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd. engages in the research and development, and industrialization of biological fermentation technology in China. It offers antibiotic intermediates, such as erythromycin thiocyanate, penicillin G potassium salt, 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodesacetoxycephalosporanic acid, desacetyl-7-aminocephalosporanic acid, and ursodeoxycholic acid. Yili Chuanning Biotechnology Co.,Ltd. was incorporated in 2010 and is based in Yining, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 2,881
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301301

Financial Performance

In 2024, SHE:301301's revenue was 5.76 billion, an increase of 19.38% compared to the previous year's 4.82 billion. Earnings were 1.40 billion, an increase of 48.88%.